ArticleInternational journal of women's health2025
Combination of Diane-35 and Cangfu Daotan Wan Effectively Ameliorates Inflammatory Response, Stress State, and Hormone Levels in Patients with Polycystic Ovary Syndrome (PCOS), Leading to Significant Improvement in Clinical Treatment Outcomes.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Cangfu Daotan decoction with Diane-35 in phlegm-dampness polycystic ovary syndrome: a meta-analysis and systematic review.Frontiers in medicine · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess the impact of combining Diane-35 with Cangfu Daotan Wan on inflammatory response, stress response, and hormone levels in patients with polycystic ovary syndrome (PCOS), and to offer insights for clinical management. Methods: A retrospective analysis was conducted from January 2022 to March 2024, encompassing PCOS patients treated at our hospital who fulfilled the inclusion criteria. Patients were categorized into two groups: the study group receiving Diane-35 plus Cangfu Daotan Wan, and the control group receiving Diane-35 alone. Comparisons were made between the two groups regarding inflammatory markers, stress response indicators, hormone levels, and overall treatment efficacy. Results: Post-treatment, the study group exhibited a lower incidence of polycystic ovarian changes and a higher overall efficacy rate compared to the control group (P<0.05). Inflammatory factors IL-6, TNF-α, and MCP-1 were significantly reduced in the study group versus the control group (P<0.05). Oxidative stress markers SOD and GSH were significantly elevated, while GSS was significantly decreased in the study group compared to the control group (P<0.05). No significant differences were observed in FSH, LH, LH/FSH ratio, or testosterone levels between the two groups (P>0.05). The BMI index was significantly lower in the study group than in the control group (P<0.05). Additionally, traditional Chinese medicine symptom scores were significantly reduced in the study group compared to the control group (P<0.05). Conclusion: The combination of Diane-35 and Cangfu Daotan Wan effectively ameliorates inflammatory response and stress state, modulates hormone levels, and enhances clinical treatment outcomes in PCOS patients. This combined therapy is both safe and efficacious, warranting further application in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.